Terms: = Breast cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Diagnosis
20 results:
1. Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative breast cancer.
Gardi N; Chaubal R; Parab P; Pachakar S; Kulkarni S; Shet T; Joshi S; Kembhavi Y; Chandrani P; Quist J; Kowtal P; Grigoriadis A; Sarin R; Govindarajan R; Gupta S
Cancer Res Commun; 2024 Feb; 4(2):404-417. PubMed ID: 38315150
[TBL] [Abstract] [Full Text] [Related]
2. LINC00963: A potential cancer diagnostic and therapeutic target.
Xie Z; Zhong C; Shen J; Jia Y; Duan S
Biomed Pharmacother; 2022 Jun; 150():113019. PubMed ID: 35462329
[TBL] [Abstract] [Full Text] [Related]
3. Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments.
Mieczkowska IK; Pantelaiou-Prokaki G; Prokakis E; Schmidt GE; Müller-Kirschbaum LC; Werner M; Sen M; Velychko T; Jannasch K; Dullin C; Napp J; Pantel K; Wikman H; Wiese M; Kramm CM; Alves F; Wegwitz F
Cell Death Dis; 2021 Nov; 12(12):1118. PubMed ID: 34845197
[TBL] [Abstract] [Full Text] [Related]
4. Timing of Presentation and Outcomes of Women with Stage IV Pregnancy-Associated breast cancer (PABC).
Matar R; Crown A; Sevilimedu V; Goldfarb SB; Gemignani ML
Ann Surg Oncol; 2022 Mar; 29(3):1695-1702. PubMed ID: 34709494
[TBL] [Abstract] [Full Text] [Related]
5. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with ezh2.
Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
[TBL] [Abstract] [Full Text] [Related]
6. The significance of enhancer of zeste homolog 2 (ezh2) expression in spindle cell lesions of the breast.
Genco IS; Hackman K; Morrar D; Jin C; Santagada E; Hajiyeva S
Pathol Int; 2021 Jun; 71(6):415-419. PubMed ID: 33730427
[TBL] [Abstract] [Full Text] [Related]
7. The diagnostic utility of ezh2 H-score and Ki-67 index in non-invasive breast apocrine lesions.
Vougiouklakis T; Belovarac BJ; Lytle A; Chiriboga L; Ozerdem U
Pathol Res Pract; 2020 Sep; 216(9):153041. PubMed ID: 32825929
[TBL] [Abstract] [Full Text] [Related]
8. IGSF1: A novel oncogene regulates the thyroid cancer progression.
Guan Y; Wang Y; Bhandari A; Xia E; Wang O
Cell Biochem Funct; 2019 Oct; 37(7):516-524. PubMed ID: 31343762
[TBL] [Abstract] [Full Text] [Related]
9. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma.
Karantanos T; Rooper L; Kang Y; Lin CT; Wenga P; Sagorsky S; Lauring J; Kang H
Oncologist; 2019 Feb; 24(2):146-150. PubMed ID: 30297384
[TBL] [Abstract] [Full Text] [Related]
11. Atypical Ductal Lesions of the breast: Criteria, Significance, and Laboratory Updates.
East EG; Carter CS; Kleer CG
Arch Pathol Lab Med; 2018 Oct; 142(10):1182-1185. PubMed ID: 30281370
[TBL] [Abstract] [Full Text] [Related]
12. ezh2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses' Health Studies.
Beca F; Kensler K; Glass B; Schnitt SJ; Tamimi RM; Beck AH
Breast Cancer Res; 2017 Mar; 19(1):21. PubMed ID: 28253895
[TBL] [Abstract] [Full Text] [Related]
13. Stromal cells in phyllodes tumors of the breast are enriched for ezh2 and stem cell marker expression.
Zhang Y; Liss AL; Chung E; Pierce LJ; Kleer CG
Breast Cancer Res Treat; 2016 Jul; 158(1):21-28. PubMed ID: 27290698
[TBL] [Abstract] [Full Text] [Related]
14. LncRNAs: key players and novel insights into cervical cancer.
Peng L; Yuan X; Jiang B; Tang Z; Li GC
Tumour Biol; 2016 Mar; 37(3):2779-88. PubMed ID: 26715267
[TBL] [Abstract] [Full Text] [Related]
15. A Gene Regulatory Program in Human breast cancer.
Li R; Campos J; Iida J
Genetics; 2015 Dec; 201(4):1341-8. PubMed ID: 26510790
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic value of COX-2, P53, and EZH-2 evaluated by quantitative image analysis in premalignant and malignant breast lesions.
Nicolopoulou-Stamati P; Tsipis A; Chelidonis G; Patsouris E; Athanassiadou P; Gonidi M; Athanassiadou AM
Diagn Cytopathol; 2015 Apr; 43(4):294-300. PubMed ID: 25355039
[TBL] [Abstract] [Full Text] [Related]
17. ezh2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer.
Knudsen ES; Dervishaj O; Kleer CG; Pajak T; Schwartz GF; Witkiewicz AK
Cell Cycle; 2013 Jul; 12(13):2042-50. PubMed ID: 23759596
[TBL] [Abstract] [Full Text] [Related]
18. Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high ezh2 expression.
Pang J; Toy KA; Griffith KA; Awuah B; Quayson S; Newman LA; Kleer CG
Breast Cancer Res Treat; 2012 Aug; 135(1):59-66. PubMed ID: 22527102
[TBL] [Abstract] [Full Text] [Related]
19. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high ezh2 expression.
Alford SH; Toy K; Merajver SD; Kleer CG
Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565
[TBL] [Abstract] [Full Text] [Related]
20. ezh2 and ALDH-1 mark breast epithelium at risk for breast cancer development.
Kunju LP; Cookingham C; Toy KA; Chen W; Sabel MS; Kleer CG
Mod Pathol; 2011 Jun; 24(6):786-93. PubMed ID: 21399615
[TBL] [Abstract] [Full Text] [Related]
